Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

ANAVEX 2-73 trial to be initiated immediately in Germany Hoboken, NJ — March 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL)  today announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM.  The Phase I trial…

Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law

Hoboken, NJ — January 18, 2011 — Anavex Life Sciences Corp. (“Anavex”, AVXL.OB) today commented on President Obama’s signing of the National Alzheimer’s Project Act (NAPA) into law.  The passage of this landmark legislation lays the foundation for the first coordinated national plan to overcome Alzheimer’s disease. “NAPAis the largest legislative victory in many years…

Alzheimer’s Weekly Names ANAVEX 2-73 the Number One Most Promising Trial Drug in Alzheimer’s Disease and Anavex’s Phase I Clinical Program as “Trial of the Year”

Hoboken, NJ — January 6, 2011 — Anavex Life Sciences Corp. (“Anavex”, AVXL.OB) announced today that ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.  The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer’s and following…

Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease

Meets major clinical development milestone for lead compound Hoboken, NJ — December 21, 2010 — Anavex Life Sciences Corp. (“Anavex”, AVXL:OB) announced today that it has filed the regulatory submission for ANAVEX 2-73  with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead…

ANAVEX 2-73: Journal of Psychopharmacology Publishes Anti-Amnesic and Neuroprotective Data Against Amyloid Toxicity For First of a New Class in Alzheimer’s Disease

Profile comparison to donepezil, citing greater potential benefits Califon, NJ – September 13, 2010 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the Journal of Psychopharmacology has published an original paper showing that ANAVEX 2-73 and its only and active metabolite ANAVEX 19-144 alleviate neurotoxicity and cognition deficits associated with Alzheimer’s disease.…